The National Medical Products Administration approves the listing of Kumoxil capsules-瞭望新时代网-瞭望时代，放眼世界

The National Medical Products Administration approves the listing of Kumoxil capsules

2025-12-16

According to the website of the State Food and Drug Administration, recently, the State Food and Drug Administration approved the listing of Kumosili Capsules (trade name: Saitanxin), a Class 1 innovative drug declared by Zhengda Tianqing Pharmaceutical Group Co., Ltd., which is applicable to adult patients with locally advanced or metastatic breast cancer who have hormone receptor (HR) positive and human epidermal growth factor receptor 2 (HER2) negative disease progression after previous endocrine treatment, and who are treated jointly with fluoxetine. The drug's launch provides patients with new treatment options. (New Society)

Edit：Wang Shu Ying Responsible editor：Li Jie

Source：people.cn

Special statement: if the pictures and texts reproduced or quoted on this site infringe your legitimate rights and interests, please contact this site, and this site will correct and delete them in time. For copyright issues and website cooperation, please contact through outlook new era email：lwxsd@liaowanghn.com

Return to home page Return to list